ANTICANCER ACTIVITIES OF CHITOSAN AND CHITOSAN NANOPARTICLES AGAINST SOME CANCEROUS CELL LINES

T. Aly, M. F. Ali, Fayed Koutb, Cunshan Zhou, Sayed A. Fayed, Emam A. ELRahim, Xiaojie Yu
{"title":"ANTICANCER ACTIVITIES OF CHITOSAN AND CHITOSAN NANOPARTICLES AGAINST SOME CANCEROUS CELL LINES","authors":"T. Aly, M. F. Ali, Fayed Koutb, Cunshan Zhou, Sayed A. Fayed, Emam A. ELRahim, Xiaojie Yu","doi":"10.21065/19204159.12.1","DOIUrl":null,"url":null,"abstract":"Cancer is considering a major leading cause of mortality. Nanotechnology holds a gold promise to develop cancer drug delivery and treatment. The present study aimed to compare in-vitro anticancer activities of chitosan (CS) and chitosan nanoparticles (CSN) against MCF7, PC3, HCT116 and A549 cell lines. The nanoparticles physic-chemical properties were estimated by Transmission Electron Microscopy (TEM) and Fourier Transform Infrared analysis (FTIR) through size and zeta potential analysis. In the current study, the results revealed that, the average diameter and zeta potential of CSN were 116.5 nm and 6.43 mV, respectively. Subsequently, CSN showed the anticancer activity with the LC50 values of 101.28 I¼g/mL in MCF7, 367.65 I¼g/mL in PC3, 666.67 I¼g/mL in HCT116 and 681.82 I¼g/mL in A549, whereas CS gave the LC50 values of 102.67 I¼g/mL in MCF7, 694.44 I¼g/mL in PC3, 1470.59 I¼g/mL in HCT116 and 769.23 I¼g/mL in A549. This study concluded that CSN were better than those obtained from CS as anticancer agent","PeriodicalId":15238,"journal":{"name":"Journal of Applied Pharmacy","volume":"18 1","pages":"1-10"},"PeriodicalIF":0.0000,"publicationDate":"2020-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Applied Pharmacy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21065/19204159.12.1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Cancer is considering a major leading cause of mortality. Nanotechnology holds a gold promise to develop cancer drug delivery and treatment. The present study aimed to compare in-vitro anticancer activities of chitosan (CS) and chitosan nanoparticles (CSN) against MCF7, PC3, HCT116 and A549 cell lines. The nanoparticles physic-chemical properties were estimated by Transmission Electron Microscopy (TEM) and Fourier Transform Infrared analysis (FTIR) through size and zeta potential analysis. In the current study, the results revealed that, the average diameter and zeta potential of CSN were 116.5 nm and 6.43 mV, respectively. Subsequently, CSN showed the anticancer activity with the LC50 values of 101.28 I¼g/mL in MCF7, 367.65 I¼g/mL in PC3, 666.67 I¼g/mL in HCT116 and 681.82 I¼g/mL in A549, whereas CS gave the LC50 values of 102.67 I¼g/mL in MCF7, 694.44 I¼g/mL in PC3, 1470.59 I¼g/mL in HCT116 and 769.23 I¼g/mL in A549. This study concluded that CSN were better than those obtained from CS as anticancer agent
壳聚糖及壳聚糖纳米颗粒对某些癌细胞的抗癌作用
癌症被认为是导致死亡的主要原因。纳米技术在开发癌症药物输送和治疗方面有着光明的前景。本研究旨在比较壳聚糖(CS)和壳聚糖纳米颗粒(CSN)对MCF7、PC3、HCT116和A549细胞的体外抗癌活性。采用透射电子显微镜(TEM)和傅里叶变换红外光谱(FTIR)对纳米颗粒的理化性质进行了表征。本研究结果表明,CSN的平均直径为116.5 nm, zeta电位为6.43 mV。随后,CSN显示出抗癌活性,MCF7的LC50值为101.28 I¼g/mL, PC3为367.65 I¼g/mL, HCT116为666.67 I¼g/mL, A549为681.82 I¼g/mL,而CS的LC50值为MCF7的102.67 I¼g/mL, PC3为694.44 I¼g/mL, HCT116为1470.59 I¼g/mL, A549为769.23 I¼g/mL。本研究表明,CSN的抗癌效果优于CS
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信